BioCentury | Mar 12, 2012
Clinical News

Angeliq drospirenone/estradiol regulatory update

...FDA approved a 0.25 mg/0.5 mg dose of Angeliq drospirenone/estradiol to treat moderate to severe vasomotor...
...due to menopause in women who have a uterus. Bayer already markets 0.5 mg/1 mg drospirenone/estradiol...
...of drospirenone, an estrogen, and estradiol, a progestin. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Angeliq drospirenone/estradiol...
BioCentury | Sep 20, 2004
Clinical News

Angeliq estradiol/drospirenone regulatory update

...SHR subsidiary Berlex Laboratories (Montville, N.J.) received an FDA approvable letter for Angeliq tablets, a once-daily...
...Angeliq already has EU approval for this indication. Schering AG (FSE:SCH; SHR), Berlin, Germany Product: Angeliq...
BioCentury | Sep 15, 2004
Company News

Berlex receives Angeliq approvable letter

...Berlex received an FDA approvable letter for its Angeliq oral, once-daily estradiol and drospirenone low dose...
...SHR), expects final approval for Angeliq in 2005. In 2003, SCH received EU approval for Angeliq...
BioCentury | Jun 28, 2004
Strategy

Schering's core pipeline

...dose estradiol Osteoporosis Approved in U.S.; registration in EU (U.S. launch 2004; EU launch 2005) Angeliq...
BioCentury | Jul 14, 2003
Clinical News

Angeliq oral once-daily estradiol and drospirenone low dose hormone replacement therapy regulatory update

...SCH said the EU concluded the Mutual Recognition approval procedure for Angeliq and that the company...
...that the company will launch the product this fall. The reference state, the Netherlands, approved Angeliq...
...osteoporosis in women (see BioCentury, Dec. 23, 2002). Schering AG (FSE:SCH; SHR), Berlin, Germany Product: Angeliq...
BioCentury | Dec 23, 2002
Clinical News

Angeliq oral once-daily estradiol and drospirenone regulatory update

...The Netherlands granted marketing approval to SCH for its Angeliq hormone replacement therapy (HRT) to treat...
...the FDA issued a non-approvable letter for Angeliq to treat menopausal symptoms. SCH will launch Angeliq...
...Europe's mutual recognition procedure within the next year. Schering AG (FSE:SCH; SHR), Berlin, Germany Product: Angeliq...
BioCentury | Dec 18, 2002
Company News

Angeliq approved in the Netherlands

...The Netherlands granted marketing approval to Schering (FSE:SCH; SHR) for its Angeliq oral once-daily estradiol and...
...the FDA issued a non-approvable letter for Angeliq to treat menopausal symptoms. SCH will launch Angeliq...
BioCentury | Oct 21, 2002
Clinical News

Angeliq oral once-daily estradiol and drospirenone regulatory update

...SCH subsidiary Berlex Laboratories (Montville, N.J.) received a non-approvable letter from the FDA for Angeliq HRT...
...not discuss the contents of the FDA letter. Schering AG (FSE:SCH; SHR), Berlin, Germany Product: Angeliq...
BioCentury | Oct 18, 2002
Company News

Schering gets another HRT non-approvable letter

...Schering (FSE:SCH; SHR) received a non-approvable letter from FDA for its Angeliq oral once-daily estradiol and...
Items per page:
1 - 9 of 9